EverSource Wealth Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

EverSource Wealth Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256	Sell	32 -4	-11%	-$34	﹤0.01%	4223
2026 Q1	$288	Buy	36 +27	+300%	+$259	﹤0.01%	4155
2025 Q4	$105	Buy	+9	New	+$88	﹤0.01%	4095
2025 Q3	–	Sell	-6	Closed	-$105	–	4460
2025 Q2	$105	Buy	+6	New	+$87	﹤0.01%	4124
2025 Q1	–	Sell	-5	Closed	-$53	–	4164
2024 Q4	$53	Buy	+5	New	+$70	﹤0.01%	3630

Other funds holding SPRY

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

IMA

Investment Management Associates Greenwood Village, Colorado $487M AUM 11.51% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

EverSource Wealth Advisors's SPRY Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 11% in Q2 2026, selling an estimated $34 and leaving 32 shares worth $256. The position accounts for ﹤0.01% of the portfolio, ranked #4223.

EverSource Wealth Advisors first reported a position in SPRY in Q4 2024 and has held it in 5 quarters since. The position peaked at $288 in Q1 2026. 41 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

EverSource Wealth Advisors held 32 shares of ARS Pharmaceuticals worth $256 as of Q2 2026.
EverSource Wealth Advisors sold 4 ARS Pharmaceuticals shares in Q2 2026, an estimated $34.
ARS Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4223 holding.
EverSource Wealth Advisors first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
EverSource Wealth Advisors's ARS Pharmaceuticals position peaked at $288 in Q1 2026.
41 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.